Anti-angiogenic Therapy in Patients with Advanced Gastric and Gastroesophageal Junction Cancer: A Systematic Review.

Cancer Res Treat · 2017 · PMC5654167 · PMID 28052652

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In the phase III AVAGAST study, high VEGF-A (HR, 0.72; 95% CI, 0.57 to 0.93) and low neuropilin-1 (HR, 0.75; 95% CI, 0.59 to 0.97) showed a trend for improved OS; however, these findings were only found to be statistically significant in patients from non-Asian regions [ 61 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.